0
Original Research: Diffuse Lung Disease |

Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid ArthritisRheumatoid Arthritis and Interstitial Lung Disease

Tracy J. Doyle, MD, MPH; Paul F. Dellaripa, MD; Kerri Batra, MD; Michelle L. Frits, BA; Christine K. Iannaccone, MPH; Hiroto Hatabu, MD, PhD; Mizuki Nishino, MD; Michael E. Weinblatt, MD; Dana P. Ascherman, MD; George R. Washko, MD, MMSc; Gary M. Hunninghake, MD, MPH; Augustine M. K. Choi, MD; Nancy A. Shadick, MD, MPH; Ivan O. Rosas, MD, FCCP
Author and Funding Information

From the Pulmonary and Critical Care Division (Drs Doyle, Washko, Hunninghake, Choi, and Rosas), Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; Division of Rheumatology, Immunology and Allergy (Drs Dellaripa, Weinblatt, and Shadick and Mss Frits and Iannaccone), Center for Pulmonary Functional Imaging (Drs Hatabu and Nishino), Department of Radiology (Drs Hatabu and Nishino), and Channing Laboratory (Dr Hunninghake), Brigham and Women’s Hospital, Boston, MA; Division of Rheumatology (Dr Batra), Rhode Island Hospital, Providence RI; Division of Rheumatology (Dr Ascherman), University of Miami Miller School of Medicine, Miami FL; and Lovelace Respiratory Research Institute (Dr Rosas), Albuquerque, NM.

CORRESPONDENCE TO: Ivan O. Rosas, MD, FCCP, Pulmonary and Critical Care Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St, Thorn 9, Boston, MA 02115; e-mail: irosas@rics.bwh.harvard.edu


FOR EDITORIAL COMMENT SEE PAGE 8

FUNDING/SUPPORT: Dr Doyle is supported by the KL2/Catalyst MeRIT Program [Grant 8KL2TR000168-05]. Drs Nishino, Hunninghake, and Rosas are supported by the US National Institutes of Health (NIH) [Grant K23 CA157631 (National Cancer Institute) to Dr Nishino, Grants K08 HL092222 and R01 HL111024 to Dr Hunninghake, and Grant K23 HL087030 to Dr Rosas]. The Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study is currently sponsored by Crescendo Bioscience Inc, MedImmune LLC, and Bristol-Myers Squibb Co.

Parts of this article have been presented or published in abstract form (17th International Colloquium on Lung & Airway Fibrosis, October 1, 2012, Modena, Italy, and Doyle TJ, Batra K, Frits ML, et al. Am J Resp Crit Care Med. 2013;187[1_MeetingAbstracts]:A22).

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2014;146(1):41-50. doi:10.1378/chest.13-1394
Text Size: A A A
Published online

BACKGROUND:  Approximately 10% of patients with rheumatoid arthritis (RA) have interstitial lung disease (ILD), and one-third have subclinical ILD on chest CT scan. In this study, we aimed to further characterize functional decrements in a spectrum of RA-associated ILD.

METHODS:  All subjects were enrolled in the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study (BRASS). The presence of interstitial lung abnormalities (ILAs) on clinically indicated chest CT scans was determined using a previously validated sequential reading method. Univariate and multivariate analyses were used to assess the association between degree of ILAs and physiologic, functional, and demographic variables of interest.

RESULTS:  Of 1,145 BRASS subjects, 91 subjects (8%) were included in this study. Twelve had radiologically severe ILAs, 34 had ILAs, and 38 had no ILAs on CT scan. Subjects with radiologically severe ILAs were older (P = .0037), had increased respiratory symptoms (cough, P = .027; dyspnea, P = .010), and more severe RA disease (rheumatoid factor, P = .018; total swollen joints, P = .046) compared with subjects with no ILAs. Participants also had a trend toward having an increased smoking history (P = .16) and having lower FVC % predicted (77% vs 94%, P = .097) and diffusion capacity of carbon monoxide % predicted (52% vs 77%, P = .068). Similar but attenuated increases in respiratory symptoms, functional decrements, and RA disease severity were observed in subjects with ILAs compared with those with no ILAs.

CONCLUSIONS:  We have shown that patients with RA have varying degrees of ILAs that are associated with a spectrum of functional and physiologic decrements. Our findings suggest that improved risk stratification and detection of ILAs will provide a therapeutic window that could improve RA-ILD outcomes.

Figures in this Article

Sign In to Access Full Content

Want to Purchase a Subscription?

New to CHEST? Become an ACCP member to receive a full subscription to both the print and online editions.
Want to access your Institution's subscription?
Sign in to your individual user account while you are actively authenticated on this website via your institution (Learn more about institutional authentication). We will then sustain your personal access to their content/subscription for 90 days, after which you can repeat this process.

Sign In to Access Full Content

Want to Purchase a Subscription?

New to CHEST? Become an ACCP member to receive a full subscription to both the print and online editions.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543